NF2 and meningioma: However, only a subset of meningiomas harbor clinically actionable alterations, and many non-NF2 mutations in high-grade tumors are not targetable; these tumors do, however, demonstrate complex copy number alterations including several chromosomal losses and gains as well as higher mutational burden and neoantigen load [8].